Johnson & Johnson (JNJ) Highlights Sustained Efficacy in Vivacity-MG3 Trial

We recently compiled a list of the 10 Most Popular Stocks on Robinhood in 2026. Johnson & Johnson is one of the most popular stocks on Robinhood

TheFly reported on April 22 that JNJ released updated findings from its Phase 3 Vivacity-MG3 trial and ongoing extension study evaluating IMAAVY (nipocalimab-aahu) in adults with generalized myasthenia gravis. The results showed continued symptom improvement, stable disease management, and a consistent safety profile over an extended follow-up period.

The data, presented at the American Academy of Neurology 2026 Meeting, also highlighted reduced steroid use and meaningful functional outcomes. Additional analyses examined minimal symptom expression as a treatment goal. The company also confirmed that a head-to-head FcRn study is currently enrolling participants.

Johnson & Johnson (JNJ) Highlights Sustained Efficacy in Vivacity-MG3 Trial

At the same time, Johnson & Johnson (NYSE:JNJ) reported a regulatory achievement within its MedTech unit. On April 22, 2026, the company secured European CE Mark clearance for the ETHICON 4000 Stapler, a next-generation surgical device built to ensure consistent staple formation across varying tissue types.

The product incorporates advanced 3D stapling capability, an updated end-effector, and simplified reload systems, supporting both open and minimally invasive procedures in the European Union. The stapler is also expected to integrate with the OTTAVA robotic platform in the future, reflecting continued expansion in surgical technology innovation.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company founded in 1886 and based in New Brunswick, New Jersey. After spinning off Kenvue in 2023, it focuses on pharmaceuticals and MedTech.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.